Core Viewpoint - A class action securities lawsuit has been filed against Caribou Biosciences, Inc. alleging securities fraud that affected investors between July 14, 2023, and July 16, 2024 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Caribou Biosciences overstated the safety, efficacy, and durability of its product CB-010 compared to approved CAR-T cell therapies for treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) and large B-cell lymphoma (LBCL) [2]. - It is alleged that Caribou was at significant risk of having insufficient cash and liquidity to fund its business operations, including preclinical research for its allogeneic CAR-NK platform [2]. - The lawsuit suggests that these issues were likely to have a significant negative impact on Caribou's business and operations, rendering the defendants' public statements materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until February 24, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].
February 24, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against CRBU